Determining the optimal vancomycin daily dose for pediatrics: a meta-analysis

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases
• Clinical Pharmacy

Background:

• Vancomycin is a critical antibiotic for treating serious Gram-positive bacterial infections in children.
• Establishing optimal dosing regimens is essential to maximize efficacy and minimize toxicity.
• Current pediatric dosing guidelines require evaluation to ensure therapeutic targets are met.

Purpose of the Study:

• To determine the appropriate initial vancomycin dose required to achieve therapeutic targets in pediatric patients.
• To analyze existing literature to identify effective vancomycin dosing strategies for children.

Main Methods:

• A systematic literature search was conducted across PubMed, Cochrane Library, and Embase (1980-2017).
• Key terms included pediatric populations and vancomycin pharmacokinetics/pharmacodynamics.
• Data from eligible studies were analyzed using RevMan V 5.2, calculating confidence intervals and odds ratios.

Main Results:

• Out of 704 identified studies, 40 were eligible, with 20 included in the final statistical analysis.
• Vancomycin doses in the reviewed studies ranged from 40 mg/kg/day to 120 mg/kg/day.
• Significant clinical heterogeneity (I²=84%) was observed across the studies.

Conclusions:

• The meta-analysis indicated that vancomycin doses below 60 mg/kg/day were frequently inadequate.
• Lower doses often failed to achieve the desired vancomycin plasma concentrations (AUC0-24/MIC >400 or trough 10-20 mg/L).
• Higher initial doses may be necessary to effectively control pediatric bacterial infections with vancomycin.